This hub covers epilepsy and pregnancy: Seizure control, medication safety, folic acid, and planning before, during, and after pregnancy. Research summaries to support informed decisions.
No. Stopping medication suddenly can be dangerous. Medication decisions should be planned with your neurologist/OB.
Body water, metabolism, and clearance change. Some meds need dose adjustments guided by blood levels.
Not always. Many people remain stable, especially with good adherence and monitoring.
Sleep deprivation is a real risk. Planning shifts and extra support isn’t “extra,” it’s safety.
This article discusses a proposed way to personalize dosing of perampanel, a seizure medicine used in drug-resistant epilepsy.
This study looked at whether children had a higher chance of neurodevelopmental disorders if their father used valproate during the 3 months before conception, which is the time period used in the study to represent spermatogenesis.
Researchers looked at whether repeated blood levels of lamotrigine during pregnancy were associated with seizure occurrence during pregnancy or up to 6 weeks after birth, and whether these serial measurements improved prediction of seizure risk beyond baseline clinical factors.
This paper was a scoping review, which means the authors gathered and summarized existing research rather than running one new experiment.
This study looked at whether early brain tests could help identify which babies might later develop epilepsy after a neonatal stroke.
This study looked at 80 fetuses found before birth to have one or more cardiac rhabdomyomas, which are heart tumors often linked with tuberous sclerosis complex (TSC).
This Australian semiprospective cohort study looked at whether children exposed to one antiseizure medication during pregnancy had different thinking and learning outcomes than children who were not exposed to antiseizure medicines before birth.
This paper is a seminar-style review about epilepsy care in adults with intellectual developmental disorders (IDD).
This study looked at the risk of major congenital malformations in babies born to women who used common antiseizure medicine combinations during the first 12 weeks of pregnancy.